According to the report, the immunology market was valued at $110.1 billion in 2023, and is estimated to reach $204.0 billion by 2033, growing at a CAGR of 6.3% from 2024 to 2033. Prime determinants of growth include the increase in prevalence of chronic diseases, rise in awareness and understanding of immune-related diseases, and increase in investment in research and development. However, stringent regulatory requirements restrict market growth. Advancements in biotechnology and molecular biology offer remunerative opportunities for the expansion of the global immunology market.\n\nRecent developments include: In March 2024, Gilead Sciences, Inc. and Xilio Therapeutics, Inc. announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies. In May 2023, Gilead Sciences, Inc. and Arcus Biosciences, Inc. expanded their previously announced research collaboration focused on oncology to include therapies for inflammatory diseases, broadening Arcus’ capabilities beyond oncology into inflammation.\n\nBy product type, the biopharmaceuticals segment dominated the market share in 2023 due to their targeted and precise mechanisms of action, resulting in enhanced efficacy and safety profiles compared to conventional drugs. Ongoing therapeutic innovations, expanding indications, increased R&D investment, and advancements in biotechnology and personalized medicine are driving segment growth.\n\nBy application, the autoimmune disease segment dominated the market share in 2023, driven by the increasing prevalence of autoimmune disorders worldwide. Growing awareness and improved diagnostic techniques have led to more cases being identified, increasing demand for effective therapies.\n\nBy end user, the hospitals and clinics segment dominated the market share in 2023. These settings serve as primary points of care for patients with immunological disorders, providing comprehensive diagnostic, therapeutic, and follow-up services. The rise in prevalence of autoimmune and inflammatory conditions necessitates increased access to specialized healthcare facilities for timely diagnosis and treatment, driving segment growth. Additionally, hospitals and clinics serve as hubs for clinical research and trials, supporting innovation and advancements in immunology treatments.\n\nRegionally, North America is expected to dominate by 2033, owing to advanced healthcare systems, rising prevalence of chronic conditions, and greater healthcare accessibility. These regions also feature significant R&D activities, leading to innovative therapies. In emerging markets such as Asia-Pacific and LAMEA, the market is experiencing rapid growth due to increasing healthcare expenditure, expanding pharmaceutical industries, and rising awareness about immunological conditions.\n\nKey players in the market include AbbVie Inc., Johnson & Johnson, Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company, Gilead Sciences, Inc., and Sanofi.

Gilead stock rating reiterated at Overweight by Cantor Fitzgerald

Cantor Fitzgerald has reiterated its stock rating for Gilead Sciences at Overweight, citing strong growth potential in the global immunology market. The market was valued at $110.1 billion in 2023 and is projected to reach $204.0 billion by 2033, growing at a CAGR of 6.3%. Key drivers include rising prevalence of chronic diseases, increased awareness of immune-related conditions, and higher R&D investment. Regulatory constraints remain a challenge. Recent developments include Gilead's exclusive license agreement with Xilio Therapeutics for the tumor-activated IL-12 program XTX301, and an expanded collaboration with Arcus Biosciences to include inflammatory diseases. Biopharmaceuticals and autoimmune disease segments dominate market share, with hospitals and clinics as the primary end users. North America is expected to lead the market by 2033, followed by rapid growth in Asia-Pacific and LAMEA. Major market players include AbbVie, Johnson & Johnson, Pfizer, Novartis, Merck, Bristol-Myers Squibb, Amgen, Eli Lilly, and Gilead Sciences.